ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences
Leerink Partners7th Annual Global Healthcare Conference
February 15 at 3:30pm ET
RBC Capital Markets2018 Global Healthcare Conference
February 21 at 2:35pm ET
Cowen and Company38th Annual Health Care Conference March 13at 8:40am ET
A webcast of each presentation will be accessible through the Investors section of the Company's website, www.immunogen.com. Following the live webcast, a replay will be available at the same location for approximately two weeks.
ImmunoGen is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its proprietary ADC technology. The Company’s lead product candidate, mirvetuximab soravtansine, is in a Phase 3 trial for FRα-positive platinum-resistant ovarian cancer, and is in a Phase 1b/2 trial in combination regimens for earlier-stage disease. ImmunoGen has three additional clinical-stage product candidates, two of which are being developed in collaboration with
Kadcyla® is a registered trademark of Genentech, a member of
This press release includes forward-looking statements. For these statements, ImmunoGen claims the protection of the safe harbor for forward-looking statements provided by the Private Securities Litigation Reform Act of 1995. It should be noted that there are risks and uncertainties related to the development of novel anticancer products, including risks related to preclinical and clinical studies, their timings and results. A review of these risks can be found in ImmunoGen's Transition Report on Form 10-K for the fiscal year ended December 31, 2016 and other reports filed with the Securities and Exchange Commission.
Sarah Kiely, 781-895-0600
Courtney O’Konek, 781-895-0600
FTI Consulting Inc.
Robert Stanislaro, 212-850-5657